Loading
Life sciences · Journal article
Trends in Immunotherapy · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Endometrial hyperplasia (EH) is a precursor to carcinoma, with the risk amplified by obesity, polycystic ovary syndrome, insulin resistance, and delayed childbearing through estrogen excess and anovulatory “unopposed estrogen” states. This review synthesizes endocrine, metabolic, molecular, diagnostic, and therapeutic evidence in EH, distinguishing findings from unvalidated mechanisms to inform biomarker development without displacing histopathology. The literature was searched in PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar (January 2000–March 2026; 2020 onward) using terms spanning EH/Endometrial intraepithelial neoplasia, cytokines, oxidative stress, PI3K/AKT/mTOR, obesity, microbiome, and biomarkers; English-language studies, reviews, meta-analyses, and guidelines were weighted toward human EH data, guided by the Scale, without a formal risk-of-bias tool. Evidence supports endocrine driving: estrogen receptor signaling promotes proliferation via cyclins and PI3K/AKT and MAPK pathways, whereas progesterone loss facilitates persistence. EH shows elevated interleukin-6 (IL-6), TNF-α, IL-1β, and IL-8, engaging NF-κB/STAT3 circuits, although limited. Oxidative stress may affect progression through reactive oxygen species-driven peroxidation and DNA (Deoxyribonucleic Acid) damage. Recurrent alterations (PTEN loss; PIK3CA, KRAS, and β-catenin changes) inform the stratification and therapy resistance in atypical EH/Endometrial intraepithelial neoplasia. Histopathology remains central, with immunohistochemistry. Clinically, levonorgestrel-releasing intrauterine system shows superior regression compared to progestins, and metformin is adjunctive. The rate of occult carcinoma at hysterectomy was 45.3%. Fertility-sparing levonorgestrel-releasing intrauterine system is effective but carries a risk of disease progression/recurrence. Overall, EH is hormone-driven and involves metabolic, inflammatory, oxidative, and molecular modifiers. Precision care requires the prospective validation of biomarker panels beyond histology and clinical risk.